FDA issues imaging drug guidance
This article was originally published in The Gray Sheet
Executive Summary
Recommendations on assessing imaging agent safety, designing clinical development programs and tailoring them to reflect the use of the agents are outlined in guidance titled "Developing Medical Imaging Drug and Biological Products," which addresses contrast agents and diagnostic radiopharmaceuticals in various imaging modalities, including CT, MRI, SPECT and PET. The guidance originally was released in 1998 as a single draft document to address in vivo radiopharmaceuticals for diagnostic and monitoring use (1"The Gray Sheet" May 24, 1999, p. 9). In 2003, the draft was divided into three sections to make it more user-friendly...
You may also be interested in...
Radiopharmaceutical Indications Need Not Be Disease-Specific - Final Rule
FDA's final rule on "Regulations for In Vivo Radiopharmaceuticals Used for Diagnosis and Monitoring," allows sponsors to propose indications that refer to a "biochemical, physiological, anatomical, or pathological process or to more than one disease or condition" in cases where the radiopharmaceutical "is not intended to provide disease-specific information."
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.